TABLE 3

Participant demographics and clinical characteristics at baseline

VariableControl armIntervention armOverall
N Mean (SD)/n (%) N Mean (SD)/n (%) N Mean (SD)/n (%)
Demographic data: numeric
Age (years)30330.3 (10.8)30431.1 (10.6)60730.7 (10.7)
Weight (kg)30363.2 (14.2)30464.1 (14.1)60763.7 (14.1)
Height (cm)303167.2 (9.2)304167.7 (9.5)607167.5 (9.4)
BMI (kg/m2)30322.5 (4.2)30422.7 (4.2)60722.6 (4.2)
Demographic data: categorical
Gender
 Female303154 (50.8)304156 (51.3)607310 (51.1)
 Male303149 (49.2)304148 (48.7)607297 (48.9)
Deprivation
 1st quintile30251 (16.9)30250 (16.6)604101 (16.7)
 2nd quintile30271 (23.5)30259 (19.5)604130 (21.5)
 3rd quintile30266 (21.9)30263 (20.9)604129 (21.4)
 4th quintile30267 (22.2)30263 (20.9)604130 (21.5)
 5th quintile30247 (15.6)30267 (22.2)604114 (18.9)
Clinical characteristics: numeric
FEV1% predicted30258.3 (22.6)30460.7 (23.5)60659.5 (23.1)
i.v. therapy-days in previous 12 months30327.7 (33)30424.2 (27.9)60725.9 (30.6)
Subjective adherence (%)29869 (30.8)30069.9 (31)59869.4 (30.9)
Numerator-adjusted normative adherence (weeks 1 and 2 post consent) (%)29545.6 (34.2)29654.0 (32.9)59149.8 (33.8)
Clinical characteristics: categorical
Chronic Pseudomonas infection299175 (58.5)304174 (57.2)603349 (57.9)
Non-chronic Pseudomonas infection299124 (41.5)304130 (42.8)603254 (42.1)
Reproduced with permission from Wildman.44 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.

From: Work packages 3.2, 3.3 and 3.4: full-scale randomised controlled trial with concurrent process evaluation

Cover of An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT
An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT.
Programme Grants for Applied Research, No. 9.11.
Wildman MJ, O’Cathain A, Hind D, et al.
Southampton (UK): NIHR Journals Library; 2021 Oct.
Copyright © 2021 Wildman et al. This work was produced by Wildman et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
Parts of this section are reproduced or adapted with permission from Wildman et al.44 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.